drugset / Trial / NCT02567370

Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581

NCT02567370 ↗

Phase 1 Completed 70 enrolled Amgen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body, safety and tolerability of AMG 581 in healthy participants and subjects with schizophrenia.

Timeline

Start
2015-08
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator AMG 581 Unknown — Oral

Indications